Rootsaert’s Insider Buy Signals Growth for VolitionRx’s Cancer‑Detection Pipeline
Insider buying at VolitionRx signals management confidence after a strong Phase II trial. Discover how Rootsaert’s $0.28 purchase could foreshadow FDA filings, new partnerships, and growth potential, while assessing the company’s risks.
4 minutes to read